Anixa Biosciences Inc

Anixa Biosciences Inc operates in the Pharmaceutical Preparations industry (SIC 2834), advancing human therapeutics and diagnostic assays through proprietary immunotherapy platforms and adaptive vaccine programs that aim to serve oncologists, hospitals, and specialty biopharma partners seeking differentiated assets. The company’s biotechnology services combine antigen design, biomarker testing, and clinical trial support to help research-driven customers accelerate translational medicine while striving for regulatory compliance across FDA and international guidelines. Management notes that limited revenues, dependency on third-party manufacturing, evolving safety data, and the inherently lengthy approval pathways typical of pharmaceutical development drive material risks, so investors should monitor capital needs and milestone execution. Anixa maintains its public disclosure via filings such as the recently filed Form 10-Q filed Sep 1999, and trading under ticker ANIX reflects the strong oversight attached to these disclosures; CIK 715446 anchors the public record. View live SEC filings on Earnings Feed.

Source: Earnings Feed research · last updated 11/24/2025